Physical activity and exercise capacity in patients with moderate COPD exacerbations

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 340-349

  Alahmari, Ayedh D ^a   Kowlessar, Beverly S ^b   Patel, Anant R C ^a   Mackay, Alex J ^a   Allinson, James P ^b   Wedzicha, Jadwiga A ^b   Donaldson, Gavin C ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE;

6 MIN WALKING DISTANCE; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; EXERCISE; EXERCISE TEST; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; INFLAMMATORY DISEASE; MALE; MUSCLE CONTRACTION; MUSCLE STRENGTH; OUTPATIENT CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY REHABILITATION; QUADRICEPS FEMORIS MUSCLE; QUADRICEPS MAXIMUM VOLUNTARY CONTRACTION; SCORING SYSTEM; SYSTEMIC DISEASE; WALKING; AMBULATORY MONITORING; ENGLAND; EXERCISE TOLERANCE; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; WALK TEST;

AGED; C-REACTIVE PROTEIN; DISEASE PROGRESSION; EXERCISE; EXERCISE TOLERANCE; FATIGUE; FEMALE; HUMANS; INFLAMMATION; LONDON; MALE; MIDDLE AGED; MONITORING, AMBULATORY; MUSCLE STRENGTH; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUADRICEPS MUSCLE; TIME FACTORS; TREATMENT OUTCOME; WALK TEST;

EID: 84980051694     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01105-2015     Document Type: Article

References (42)

1. Baghai-Ravary R, Quint JK, Goldring JJ, et al. Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med 2009; 103: 216-223.
2. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
3. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874.
4. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
5. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
6. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 446-452.
7. Alahmari AD, Patel AR, Kowlessar BS, et al. Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2014; 14: 98.
8. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest 2006; 129: 536-544.
9. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-756.
10. Cotes JE, Zejda J, King B. Lung function impairment as a guide to exercise limitation in work-related lung disorders. Am Rev Respir Dis 1988; 137: 1089-1093.
11. Hopkinson NS, Man WD, Dayer MJ, et al. Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 137-142.
12. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
13. Alahmari AKB, Patel A, Mackay A, et al. The relationship between exercise capacity and inflammatory markers at COPD exacerbation. Thorax 2014; 69: Suppl. 2, A19.
14. Patel AKB, Mackay A, Singh R, et al. COPD exacerbation frequency phenotype and exercise capacity. Am J Respir Crit Care Med 2013; 187: A1440.
15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
16. Edwards RH, Young A, Hosking GP, et al. Human skeletal muscle function: description of tests and normal values. Clin Sci Mol Med 1977; 52: 283-290.
17. Tennant KF. Assessment of fatigue in older adults: the FACIT Fatigue Scale (version 4). Ann Longterm Care 2011; 19.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
19. Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 943-950.
20. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012; 106: 522-530.
21. Patel SA, Benzo RP, Slivka WA, et al. Activity monitoring and energy expenditure in COPD patients: a validation study. COPD 2007; 4: 107-112.
22. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013; 187: 382-386.
23. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
24. Quint JK, Donaldson GC, Hurst JR, et al. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J 2011; 37: 501-507.
25. Newell SZ, McKenzie DK, Gandevia SC. Inspiratory and skeletal muscle strength and endurance and diaphragmatic activation in patients with chronic airflow limitation. Thorax 1989; 44: 903-912.
26. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506-512.
27. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61: 10-16.
28. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
29. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
30. Hung J, Goldwater D, Convertino VA, et al. Mechanisms for decreased exercise capacity after bed rest in normal middle-aged men. Am J Cardiol 1983; 51: 344-348.
31. Corcoran PJ. Use it or lose it -the hazards of bed rest and inactivity. West J Med 1991; 154: 536-538.
32. Argilés JM, Busquets S, Felipe A, et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2005; 37: 1084-1104.
33. Langen RC, Schols AM, Kelders MC, et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J 2001; 15: 1169-1180.
34. Schaap LA, Pluijm SMF, Deeg DJ, et al. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006; 119: 526.e9-e17.
35. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-355.
36. Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000; 15: 274-280.
37. Donaldson GC, Mullerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res 2013; 14: 79.
38. Quint JK, Baghai-Ravary R, Donaldson GC, et al. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32: 53-60.
39. Cooper CB. Desensitization to dyspnea in COPD with specificity for exercise training mode. Int J Chron Obstruct Pulmon Dis 2009; 4: 33-43.
40. Puhan MA, Scharplatz M, Troosters T, et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -a systematic review. Respir Res 2005; 6: 54.
41. Eaton T, Young P, Fergusson W, et al. Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology 2009; 14: 230-238.
42. Rutherford OM, Jones DA, Newham DJ. Clinical and experimental application of the percutaneous twitch superimposition technique for the study of human muscle activation. J Neurol Neurosurg Psychiatry 1986; 49: 1288-1291.